Veru Inc.
VERU Healthcare Biotechnology
In the quarter to June 2026, EPS grew 40.0% and free cash flow was flat, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three; insiders bought in the last twelve months.
Follow VERU
Veru Inc. (VERU) EV/Sales
As of 16 October 2026, Veru Inc. (VERU) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.0× (January 2024) to 34.5× (August 2022); the current reading is higher than 11% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 3.3× | (4.14%) |
| FY2023 | 3.4× | (84.12%) |
| FY2022 | 21.5× | 147.80% |
| FY2021 | 8.7× | 118.03% |
| FY2020 | 4.0× | (8.80%) |
| FY2019 | 4.4× | (9.16%) |
| FY2018 | 4.8× | (12.97%) |
| FY2017 | 5.5× | 274.71% |
| FY2016 | 1.5× | 17.19% |
| FY2015 | 1.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 3.3× | (51.37%) |
| Jun 2024 | 6.7× | 51.25% |
| Mar 2024 | 4.4× | 53.17% |
| Dec 2023 | 2.9× | (14.92%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| VERU Veru Inc. | 1.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| CELU Celularity, Inc. compare | 4.1× |
| SER Serina Therapeutics, Inc. compare | 66.0× |
| GRCE Grace Therapeutics, Inc. compare | 109× |
| TIL Instil Bio, Inc. compare | 401× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)